Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.54 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | YAP1 | P46937 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569344 | 1.00 | MMP1 (0.54) | MMP1ADAM17MMP2MMP9YAP1 | |
| SCHEMBL5569242 | 0.90 | MMP1 (0.53) | MMP1ADAM17MMP2MMP9ALDH1A1 | |
| SCHEMBL5569247 | 0.90 | MMP1 (0.53) | MMP1ADAM17MMP2MMP9ALDH1A1 | |
| SCHEMBL5567018 | 0.89 | MAOB (0.57) | MMP1ADAM17MMP2MMP9LIPE | |
| SCHEMBL5567015 | 0.89 | MAOB (0.57) | MMP1ADAM17MMP2MMP9LIPE | |
| SCHEMBL3508151 | 0.86 | MAOB (0.50) | ADAM17MMP2MMP9KMT2AKDM4E | |
| SCHEMBL3508153 | 0.86 | MAOB (0.50) | ADAM17MMP2MMP9KMT2AKDM4E | |
| SCHEMBL7933692 | 0.86 | FPR2 (0.54) | KMT2AL3MBTL1 | |
| SCHEMBL7414725 | 0.86 | FPR2 (0.54) | KMT2AL3MBTL1 | |
| SCHEMBL7414726 | 0.86 | FPR2 (0.54) | KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235581-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1542971-A1 | 4-PYRROLIDINO-PHENYL-BENZYL ETHER DERIVATIVES | F. Hoffmann-La Roche Ltd. (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20040097578-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-05-20 | — | — | US | disclosed |
| WO-2004026826-A1 | 4-PYRROLIDINO-PHENYL-BENZYL ETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097578-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | MAOB, MAOA, COMT | MMP1 1459/4885ADAM17 1946/4885MMP2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.